FindTrial
Sign In

Expanded Access to Venetoclax

Expanded Access to Venetoclax

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03123029
Enrollment
Unknown
Registered
2017-04-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Amyloidosis, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Non-Hodgkin's Lymphoma, Plasma Cell Leukemia

Keywords

Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme

Brief summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Interventions

DRUGVenetoclax

Venetoclax will be administered orally.

Sponsors

AbbVie
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Exclusion criteria

* There are other suitable treatment options. * The participant qualifies for ongoing clinical trials.

Contacts

CONTACTABBVIE CALL CENTER
abbvieclinicaltrials@abbvie.com844-663-3742
STUDY_DIRECTORABBVIE INC.

AbbVie

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026